Market niche Target hospitals and surgical centers focusing on wound care, burns, chronic ulcers, and soft-tissue repair, highlighting Imbed's Microlyte technology and fully synthetic, antimicrobial wound matrices.

Strategic partnerships Leverage existing distributor relationships (for example Spartan Medical) and pursue collaborations with pediatric care networks and Premier-related programs to expand adoption of PelashieldAM and other wound care products.

Regulatory credibility Emphasize FDA registration and ISO 13485 quality management in sales pitches to large healthcare systems prioritizing compliant, high-quality medical devices with scalable manufacturing.

Growth funding Highlight recent funding milestones and growth investments from Niterra and other financiers to reassure customers of company stability and ongoing product development capacity.

Product expansion Position SAM PainGuard with Lidocaine as an additional analgesia-enabled wound care option, and explore cross-sell opportunities across acute care, oral and soft-tissue repair markets leveraging the Microlyte platform.